证券研究报告 | 年报点评报告 2024年05月05日 三星医疗（601567.SH） 24Q1 海外订单持续高增，海外配用电有望持续突破 事件：公司发布2023年报及2024年一季报。2023年公司营收114.63亿 买入（维持） 元，同增 25.99%；归母净利 19.04 亿元，同增 100.79%。全年投资收益 股票信息 2.96亿元，其中长期股权投资2.3亿元。全年汇兑收益4000万以上。23Q4 行业 电网设备 单季营收 31.25亿元，同增 42.24%；归母净利 4.14亿元，同增 68.09%。 24Q1营收30.25亿元，同增34.53%；归母净利3.64亿元，同增35.15%。 前次评级 买入 4月30日收盘价(元) 33.70 配用电业务公司主要营收，24Q1海外在手订单维持高景气。 总市值(百万元) 47,557.34 总股本(百万股) 1,411.20 1）分业务看：2023 年公司配用电业务收入 84.36 亿元，同增 23.90%，毛 其中自由流通股(%) 98.85 利率34.12%（+5.49pct）；医疗服务业务收入27.83亿元，同增34.73%， 毛利率31.73%（ ...

证券研究报告 | 2024年04月30日 三星医疗（601567.SH） 买入 海外在手订单再创新高，欧洲市场优势进一步夯实 核心观点 公司研究·财报点评 业绩大幅增长，现金分红9.6亿元。23年公司实现营收114.63亿元，同比 电力设备·电网设备 +25.99%，实现归母净利润19.04亿元，同比+100.79%。全年销售毛利率 证券分析师：王蔚祺 证券分析师：王晓声 33.99%（同比+5.11pct.），扣非销售净利率14.56%（同比+2.92pct.）。23 010-88005313 010-88005231 wangweiqi2@guosen.com.cnwangxiaosheng@guosen.com.cn 年公司拟派发现金红利9.61亿元，占当期归母净利润50.47%。 S0980520080003 S0980523050002 基础数据 四季度保持业绩高增态势，毛利率同比提升。23年第四季度公司实现营收 31.25亿元（同比+42.24%，环比+12.04%），归母净利润4.14亿元（同比 投资评级 买入(维持) 合理估值 +68.09%，环比-33.12%），销售毛利率 34.98%（同 ...

证券研究报告·公司点评报告·电网设备 三星医疗（601567） 2023年报&2024 年一季报点评：业绩超预期， 2024年 04月 28日 配用电整体出海在加速 证券分析师 曾朵红 买入（维持） 执业证书：S0600516080001 021-60199793 盈[T 利ab 预le_ 测EP 与S 估] 值 2022A 2023A 2024E 2025E 2026E zengdh@dwzq.com.cn 证券分析师 朱国广 营业总收入（百万元） 9,098 11,463 14,498 18,046 21,944 执业证书：S0600520070004 同比（%） 29.55 25.99 26.48 24.48 21.60 zhugg@dwzq.com.cn 归母净利润（百万元） 948.12 1,903.70 2,347.71 2,841.97 3,543.52 证券分析师 冉胜男 同比（%） 37.40 100.79 23.32 21.05 24.69 执业证书：S0600522090008 EPS-最新摊薄（元/股） 0.67 1.35 1.66 2.01 2.51 ranshn@dwzq.com. ...

证券研究报告：电力设备 | 公司点评报告 2024年4月27日 股票投资评级 三星医疗(601567) 增持|维持 海外在手订单高增，欧洲配电订单落地 个股表现 ⚫ 投资要点 事件：三星医疗发布2023年年报及2024年一季报，2023年实现 三星医疗 电力设备 170% 营收114.63亿元（+26%）、归母净利19.04亿元（+101%），毛利率、 149% 净利率分别为33.99%、16.76%，同比提升5.11、6.15pcts，其中毛利 128% 107% 率的提升贡献盈利能力的主要增长。单季度来看，24Q1实现营收30.25 86% 65% 亿（+35%），实现归母净利 3.64 亿元（+35%），营收业绩增长符合预 44% 23% 期。 2% 智能配用电板块：2023年实现营收84.36亿元（+24%），毛利率 -19% -40% 同比提升5.5pcts至34.12%。分区域来看，海外业务收入19.61亿元 2023-04 2023-07 2023-09 2023-12 2024-02 2024-04 （+20%），毛利率同比提升2.97pcts至32.85%，国内业务收入64.75 资料来源： ...

业绩简评 2024年 4月 25 日晚公司披露年报及一季报，23年全年实现营收 114.6 亿元，同比+26%；归母净利润19.0 亿元，同比+100%，毛利 率达 33.99%，同比+5.11pct。24 年Q1 实现营收30.3 亿元，同比 增长 35%；归母净利润3.6 亿元，同比+35%。业绩符合市场预期。 经营分析 海外配用电：深耕用电及系统集成项目，积极布局配电出海业务。 目前公司海外销售网络已覆盖 70 多个国家，现拥有巴西、印尼、 波兰、墨西哥、德国 5大工厂。1）用电：已覆盖欧洲15个国家， 成为在欧洲市场覆盖国家数量最多的中国厂家，在欧洲、拉美交付 了多个智慧能源集成项目；2）配电：依托 20余年国内经验与海外 复用渠道，在中东、亚太持续突破。23 年公司海外实现营收19.6 亿元，同比+20%，24Q1 海外累计在手订单55.0 亿元，同比+58%。 国内配用电：持续夯实电网渠道优势，非电网业务快速增长。 人民币(元) 成交金额(百万元) 1）网内：持续巩固电网渠道优势，配用电产品中标金额持续行业 39.00 1,200 领先，公司在国内拥有31 个办事处，实现电网及用户市场全面覆 34 ...

证券代码：601567 证券简称：三星医疗 公告编号：临 2024-055 宁波三星医疗电气股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据财政部的要求，公司依据上述企业会计准则解释的规定对原会计政策进 行相应变更，并按文件规定的起始日开始执行。 重要内容提示： 二、本次会计政策变更对公司的影响 本次会计政策变更系公司根据财政部发布的《准则解释第 17 号》的相关规 定和要求进行的合理变更，变更后的会计政策能够更加客观、公允地反映公司的 财务状况和经营成果，符合相关法律法规的规定和公司实际情况，不涉及对公司 以前年度的重大追溯调整，不会对公司财务状况、经营成果和现金流量产生重大 影响，不存在损害公司及股东利益的情况。 三、审议程序及独立董事、监事会的结论性意见 本次会计政策变更已经 2024 年 4 月 25 日召开的公司第六届董事会第十二次 会议和第六届监事会第九次会议审议通过，独立董事发表了同意意见，无需提交 股东大会审议。 本次会计政策变更是宁波三星医疗电气股份有限公司（以下简称 ...

宁波三星医疗电气股份有限公司董事会 关于独立董事 2023 年度独立性自查情况的专项意见 根据证监会《上市公司独立董事管理办法》、《上海证券交易所股票上市规则》、 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等要求，宁波三 星医疗电气股份有限公司（以下简称"公司"）董事会，就公司在任独立董事王 溪红女士、段逸超先生、杨华军先生的独立性情况进行评估并出具如下专项意见： 经核查公司现任独立董事王溪红女士、段逸超先生、杨华军先生的任职经历 以及其签署的相关自查文件，上述人员未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关 系或其他可能妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情 况。因此，公司独立董事符合《上市公司独立董事管理办法》、《上海证券交易所 上市公司自律监管指引第 1 号——规范运作》中对独立董事独立性的相关要求。 宁波三星医疗电气股份有限公司 董事会 2024 年 4 月 25 日 ...

Dividends and Share Repurchases - The company plans to distribute a cash dividend of RMB 6.50 per 10 shares, totaling approximately RMB 908,464,595.35[2] - The total cash dividend, including share repurchases, amounts to RMB 960,832,171.85, representing 50.47% of the net profit attributable to shareholders[2] - The company's total share capital is 1,411,197,171 shares, with 13,559,332 shares repurchased[2] - The company's 2023 dividend plan is to distribute a cash dividend of 6.50 yuan per 10 shares, with an estimated total cash dividend of approximately 908,464,595.35 yuan[151] - Including the 52,367,576.50 yuan spent on share repurchases, the total cash dividend for 2023 is 960,832,171.85 yuan, accounting for 50.47% of the net profit attributable to shareholders[152] - Cash dividend amount (including tax) is RMB 908,464,595.35, accounting for 47.72% of the net profit attributable to ordinary shareholders of the company[154] - Total dividend amount (including tax) is RMB 960,832,171.85, accounting for 50.47% of the net profit attributable to ordinary shareholders of the company[155] - The company completed the registration of 4.675018 million restricted shares for the fourth and fifth phases of the restricted stock incentive plan[156] - 581,500 restricted shares were repurchased and canceled due to 24 incentive objects leaving the company[156] - 8,344,200 restricted shares were released for the first time, with a release ratio of 40%[156] - 872,900 restricted shares were repurchased and canceled due to 18 incentive objects leaving the company[157] Subsidiaries and Investments - The company's subsidiaries include Samsung Smart, Ningbo Lianneng, and Samsung Hong Kong, among others[6] - The company has a significant presence in the medical and rehabilitation sectors with subsidiaries like Ningbo Mingzhou Hospital and Wenzhou Shenlan Hospital[6] - The company has multiple wholly-owned subsidiaries including Ningbo Sanxing Medical Research Institute, Nansen Instrumentos De Precisao Ltda in Brazil, and Sanxing Smart Electric Bangladesh Co. Ltd[8] - Key subsidiaries also include Ningbo Sanxing Electric (Sweden) AB, Foxytech Sp. z o.o., and NANSEN PERU S.A.C[8] - The company holds equity stakes in various partnerships such as Ningbo Sanxing Kaiyun Medical Investment Partnership and Beijing Chunfeng Bairun Equity Investment Partnership[8] - Major subsidiaries in the energy sector include Ningbo Aogao Supply Chain Co., Ltd., Ningbo Aogao Power Development Co., Ltd., and Ningbo Aogao Power Consulting Co., Ltd[8] - The company has significant investments in technology and IoT through subsidiaries like Ningbo Sanxing Power IoT Technology Co., Ltd. and Ningbo Sanxing IoT Co., Ltd[8] - Key subsidiaries in the medical field include Ningbo Mingzhou Puhua Pharmaceutical Co., Ltd. and Ningbo Sanxing Medical Research Institute[8] - The company has a presence in the renewable energy sector with subsidiaries like Ningbo Aogao Photovoltaic Power Generation Co., Ltd. and Nansen Solar Energy Co., Ltd. in Brazil[8] - The company acquired 18 new subsidiaries during the reporting period, expanding its consolidated financial statements[68] - The company acquired 100% equity in multiple hospitals, including Huzhou Zhebei Mingzhou Hospital and Quzhou Mingzhou Hospital[121] - The company acquired 100% equity of Huzhou Zhebei Mingzhou Hospital Co., Ltd., Yuyao Mingzhou Rehabilitation Hospital Co., Ltd., Jiaxing Mingzhou Nursing Home Co., Ltd., Quzhou Mingzhou Hospital Co., Ltd., and Quanzhou Mingzhou Rehabilitation Hospital Co., Ltd.[133] - The company acquired 100% equity of multiple hospitals, including Huzhou Zhebei Mingzhou Hospital, Yuyao Mingzhou Rehabilitation Hospital, Jiaxing Mingzhou Nursing Home, Quzhou Mingzhou Hospital, and Quanzhou Mingzhou Rehabilitation Hospital[144] - The company's subsidiary plans to acquire 100% equity of multiple hospitals for RMB 224 million[198] - The company acquired 100% equity of Huzhou Zhebei Mingzhou Hospital Co., Ltd. for a total of RMB 11,200 million[199] - The company acquired 100% equity of Yuyao Mingzhou Rehabilitation Hospital Co., Ltd. for a total of RMB 3,700 million[199] - The company acquired 100% equity of Jiaxing Mingzhou Nursing Home Co., Ltd. for a total of RMB 8,400 million[199] - The company acquired 100% equity of Quzhou Mingzhou Hospital Co., Ltd. for a total of RMB 12,900 million[199] - The company acquired 100% equity of Quanzhou Mingzhou Rehabilitation Hospital Co., Ltd. for a total of RMB 3,759.628 million[199] - The company completed the industrial and commercial registration changes for the five target hospitals in May 2023[199] - The company acquired 2.54% equity of Aokesi Intelligent Technology for RMB 3,759.628 million[199] Financial Performance - Revenue for 2023 reached RMB 11,462,508,357.39, a 25.99% increase compared to 2022[17] - Net profit attributable to shareholders in 2023 was RMB 1,903,702,022.52, up 100.79% year-over-year[17] - Operating cash flow for 2023 was RMB 1,901,306,987.04, a 55.52% increase from 2022[17] - Total assets at the end of 2023 were RMB 21,513,022,906.38, a 32.57% increase compared to 2022[17] - Basic earnings per share for 2023 was RMB 1.35, a 101.49% increase from 2022[18] - Weighted average return on equity (ROE) for 2023 was 18.51%, an increase of 8.19 percentage points from 2022[18] - Q4 2023 revenue was RMB 3,124,748,665.63, the highest among all quarters[20] - Non-operating income in 2023 included RMB 118,212,431.28 from government subsidies[21] - The company recognized RMB 64,406,482.16 in VAT refunds as recurring income due to its sustainability[24] - The company achieved operating revenue of 11.463 billion yuan, a year-on-year increase of 25.99%, and net profit attributable to shareholders of 1.904 billion yuan, a year-on-year increase of 100.79%[27] - The company's gross margin increased to 33.99%, up 5.11 percentage points year-on-year[27] - Company achieved revenue of 11.463 billion yuan, a year-on-year increase of 25.99%[61] - Net profit attributable to shareholders reached 1.904 billion yuan, a year-on-year increase of 100.79%[61] - Operating income from the manufacturing sector was 8.436 billion yuan, with a gross margin of 34.12%, an increase of 5.49 percentage points year-on-year[64] - Operating income from the medical services sector was 2.783 billion yuan, with a gross margin of 31.73%, an increase of 5.01 percentage points year-on-year[64] - Domestic operating income was 9.300 billion yuan, with a gross margin of 33.97%, an increase of 5.53 percentage points year-on-year[64] - International operating income was 1.961 billion yuan, with a gross margin of 32.85%, an increase of 2.98 percentage points year-on-year[64] - Direct sales revenue was 10.258 billion yuan, with a gross margin of 33.20%, an increase of 4.80 percentage points year-on-year[65] - Distribution sales revenue was 1.003 billion yuan, with a gross margin of 39.61%, an increase of 6.95 percentage points year-on-year[65] - Production volume of smart electricity products increased by 12% year-on-year to 25.750 million units/sets[66] - Sales volume of smart electricity products increased by 21% year-on-year to 25.444 million units/sets[66] - Manufacturing sector's main business cost increased by 14.36% year-on-year to 5,558,123,490.30 yuan[67] - Medical services sector's main business cost increased by 25.52% year-on-year to 1,899,717,301.57 yuan[67] - Operating cash flow increased by 55.52% year-on-year to 1,901,306,987.04 yuan[77] - Investment cash flow decreased significantly due to reduced receivables and increased construction investments[77] - Financing cash flow increased to 1,174,529,477.93 yuan due to increased long-term borrowing[77] - Fair value changes in non-current financial assets generated a profit of 100,688,795.43 yuan[79] - Disposal of subsidiaries and other non-current financial assets generated profits of 50,979,269.60 yuan and 27,942,470.54 yuan respectively[79] - Monetary funds increased by 85.93% to 5,452,937,584.98 yuan, mainly due to increased operating cash inflow and long-term loans[80] - Trading financial assets increased by 98.34% to 53,723,860.13 yuan, primarily due to changes in the fair value of Samsung Hong Kong stocks[80] - Inventory increased by 80.70% to 3,256,637,523.09 yuan, driven by scale growth and product/material stockpiling to meet order delivery[80] - Long-term loans surged by 1,544.00% to 2,466,000,000.00 yuan, as the company increased liquidity through additional long-term borrowing[81] - Overseas assets amounted to 1,575,977,257.21 yuan, accounting for 7.33% of total assets[83] - Total restricted assets were 749,963,385.33 yuan, including 410,251,706.66 yuan in monetary funds used as guarantees for bank transactions[85] - Total external investment reached 1,298,996,400 yuan, with 977,626,300 yuan allocated to equity investments through acquisitions and new establishments[87] - The acquisition of Zhebei Mingzhou for 224,000,000 yuan resulted in a profit impact of 5,856,200 yuan[88] - The acquisition of Yuyao Mingzhou Rehabilitation for 112,000,000 yuan resulted in a profit impact of 6,019,900 yuan[88] - The establishment of Quanzhou Mingzhou Rehabilitation for 129,000,000 yuan resulted in a profit impact of 8,639,000 yuan[88] - The company established new rehabilitation medical centers in Suzhou, Jinhua, Wuhu, Hefei, and Foshan with investments of 5,070, 3,900, 3,900, 5,200, and 4,550 thousand RMB respectively, all funded with 65% equity[89] - The company acquired Aokes Intelligent Technology for 3,759.63 thousand RMB, achieving a 100% ownership and generating a profit of 41,042.42 thousand RMB[89] - The company invested 10,000 thousand RMB in establishing Aokes Energy Storage, focusing on new energy technology R&D and equipment manufacturing[90] - The company's total investment in non-equity projects reached 97,762.63 thousand RMB, with a cumulative profit of 40,805.30 thousand RMB[90] - The company invested 32,137.01 thousand RMB in the Power Internet of Things Industrial Park project, with a cumulative investment of 107,975.40 thousand RMB[92] - The company's financial assets, including stocks, private equity funds, and derivatives, had a total fair value of 982,221.47 thousand RMB at the end of the period[93] - The company's stock investment in Modern Dental (HK3600) had an initial cost of 8,585.56 thousand RMB and a year-end fair value of 28,357.71 thousand RMB[94] - The company's commodity futures investments had a year-end fair value of 27,584.46 thousand RMB, accounting for 2.47% of the company's net assets[96] - The company's forward exchange contracts had a total investment of 21,321.15 thousand RMB, with all positions closed by the end of the period[96] - The fair value change of commodity futures contracts in the reporting period was RMB 2.2621 million, calculated based on the settlement prices of corresponding contracts on the Nanhua Futures Exchange[97] - The fair value of forward foreign exchange contracts was determined based on the difference between the contract price and the forward exchange rate at the end of the period[97] - Samsung Intelligent's total assets in 2023 were RMB 2.36837 billion, with a net profit of RMB 236.9189 million[100] - Aux Intelligent Technology's total assets in 2023 were RMB 5.0325527 billion, with a net profit of RMB 410.4242 million[100] - Ningbo Mingzhou Hospital's total assets in 2023 were RMB 1.8831204 billion, with a net profit of RMB 125.4596 million[100] - Mingzhou Medical Group's total assets in 2023 were RMB 2.355199 billion, with a net loss of RMB 28.295 million[100] - Aux Investment's total assets in 2023 were RMB 1.2562357 billion, with a net profit of RMB 142.538 million[100] Business Segments and Market Presence - The smart power distribution and utilization business generated revenue of 8.612 billion yuan, a year-on-year increase of 23.99%, with cumulative orders of 10.494 billion yuan, up 22.09% year-on-year[28] - Overseas orders for the smart power distribution and utilization business reached 4.525 billion yuan, a year-on-year increase of 42.93%, driven by rapid growth in key markets such as Europe, the Middle East, and the Americas[28] - The medical services business achieved revenue of 2.809 billion yuan, a year-on-year increase of 34.57%, with rehabilitation medical services revenue reaching 1.311 billion yuan, up 64.80% year-on-year[32] - The company expanded its hospital network to 28 hospitals, with a total of 8,868 beds, adding 10 new hospitals during the reporting period[33] - The company's overseas sales network now covers over 70 countries and regions, with new factories established in Germany and Mexico[28] - The company successfully delivered multiple smart energy integration projects in Europe and Latin America, achieving a data collection rate of over 99.9% in the Swedish PUMA smart meter project[29] - The company's overseas power distribution business made breakthroughs in the Middle East and Asia-Pacific markets, securing a project with Saudi Arabia's national power company[29] - The company launched new products in the new energy sector, including charging piles and energy storage systems, and developed an integrated "source-grid-storage-charging" business model[30] - The company's DC charging stations cover 60-480kW, with leading performance in recent years[47] - The company launched new products including residential inverters, small commercial string inverters, and residential energy storage inverters in 2023[47] - The company's smart metering products achieved industry-leading collection and line loss rates in overseas markets[47] - The company's photovoltaic box transformers received the first domestic certification, and compact ring main units have been widely used in the Middle East market[47] - The company has established 5 overseas manufacturing bases in Brazil, Indonesia, Poland, Mexico, and Germany, and 5 sales centers in Sweden, Colombia, Nepal, Peru, and Bangladesh, covering over 70 countries and regions[51] - The company's business in the European market covers 15 countries, making it the Chinese manufacturer with the most extensive coverage in Europe[51] - The company has 28 hospitals under its management, with a total of 8,868 beds, including 22 rehabilitation hospitals[57] - The company added 10 new hospitals through self-construction and acquisitions during the reporting period[57] - The company has 31 domestic offices, achieving comprehensive coverage of the power grid and user markets[51] - The company has established a global marketing platform, focusing on five major regional markets: Europe, the Middle East, Asia-Pacific, Africa, and the Americas[48] - The company has successfully passed the CMMI V2.0 L5 international certification, the highest level in the global software field[53] - The company has built a 5G+ industrial internet provincial-level digital factory, equipped with advanced manufacturing facilities such as smart meter production lines and 5G-AGV logistics systems[54] - The company has developed a comprehensive digital operation management platform, integrating systems like SAP, PLM, MES, CRM, WMS, and SRM[56] - The company has established a "large comprehensive base, strong specialized chain" medical system, with Ningbo Mingzhou Hospital becoming a third-level B comprehensive hospital in March 2023[58] Corporate Governance and Leadership - The company's legal representative is Shen Guoying, and its headquarters are located in Ningbo, Zhejiang Province[11] - The company's annual report is disclosed through major financial media outlets such as China Securities Journal, Shanghai Securities News, and Securities Times[14] - The company held a total of 5 shareholder meetings during the reporting period[113] - The company completed the board of directors' re-election, ensuring compliance with legal and regulatory requirements[114] - The company completed the board of supervisors' re-election, effectively supervising business decisions and financial status[115] - The company disclosed 104 temporary announcements in addition to regular reports during the reporting period[118] - The company held 3 performance briefings via video recording in 2023, engaging with investors on governance and strategy[119] - Chairman Shen Guoying holds 650,000 shares with no change during the year[124] - Director Zheng Jianjiang holds 179,306,730 shares with no change during the year[124] - Director Cheng Zhihao reduced his holdings by 172,000 shares to 258,000[124] - Former director Zheng Junda reduced his holdings by 497,375 shares to 50,000[124] - Total shares held by directors and supervisors decreased by 669,375 to 181,328,230[125] - Chairman Shen Guoying received a pre-tax remuneration of

（一）直接或间接地控制公司的法人（或其他组织）； （二）由上述第（一）项直接或间接控制的除本公司、控股子公司及控制其 他主体以外的法人（或其他组织）； （三）关联自然人直接或间接控制的，或者由关联自然人担任董事（不含同 为双方的独立董事）、高级管理人员的除公司、控股子公司及控制的其他主体以 外的法人（或其他组织）； 宁波三星医疗电气股份有限公司 关联交易决策制度 第一章 总 则 第一条 为规范宁波三星医疗电气股份有限公司（以下简称"公司"）与各 关联人发生的关联交易行为，维护公司及公司全体股东的合法权益，根据《中华 人民共和国公司法》、《中华人民共和国证券法》、《上海证券交易所股票上市 规则》等相关法律、法规、规范性文件以及《宁波三星医疗电气股份有限公司章 程》（以下简称"公司章程"）的规定，结合公司实际情况，制订本制度。 第二条 公司处理关联交易事项，应当遵循下列原则： 第二章 关联人与关联关系 第三条 公司关联人包括关联法人、关联自然人。 第四条 具有下列情形之一的法人（或其他组织），为公司的关联法人： （四）持有公司5%以上股份的法人（或其他组织）及其一致行动人； （五）中国证券监督管理委员会（以下简称 ...

2024 年第一季度报告 单位：元 币种：人民币 证券代码：601567 证券简称：三星医疗 宁波三星医疗电气股份有限公司 2024 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|----------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增 减变动幅度 (%) | | 营业收入 | | 3,024,788,914.34 34.53 ...